Document is current
Any future updates will be listed below
-
Authors
Wei, Yun
Qin, Qian
Yan, Chuan http://orcid.org/0000-0002-0449-7072
Hayes, Madeline N.
Garcia, Sara P.
Xi, Haibin
Do, Daniel
Jin, Alexander H. http://orcid.org/0000-0002-7431-1456
Eng, Tiffany C.
McCarthy, Karin M.
Adhikari, Abhinav
Onozato, Maristela L.
Spentzos, Dimitrios http://orcid.org/0000-0001-8455-4809
Neilsen, Gunnlaugur P.
Iafrate, A. John
Wexler, Leonard H.
Pyle, April D. http://orcid.org/0000-0001-6122-1649
Suvà, Mario L. http://orcid.org/0000-0001-9898-5351
Dela Cruz, Filemon
Pinello, Luca http://orcid.org/0000-0003-1109-3823
Langenau, David M. http://orcid.org/0000-0001-6664-8318
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01AR064327, R00HG008399, R01CA215118)
- License Information
-
More Information
Article History
Received: 8 June 2021
Accepted: 24 June 2022
First Online: 18 August 2022
Competing interests
: A.J.I. receives royalties from ArcherDx and consults for Paige.AI, Repare Therapeutics, Oncoclinicas Brasil and Kinnate Biopharma. M.L.S. is an equity holder, scientific co-founder and advisory board member of Immunitas Therapeutics. L.P. has financial interests in Edilytics and SeQure Dx, Inc. All potential competing interests are reviewed and managed by Massachusetts General Hospital and Mass General Brigham HealthCare in accordance with their conflict-of-interest policies. D.M.L. receives sponsored research funds from NextCure for an unrelated project.
